PCM
FPRX

Piermont Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Piermont Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-32,504
Closed -$1.63M – 282
2016
Q4 		$1.63M Sell
32,504
-2,215
-6% -$116K 0.37% 108
2016
Q3 		$1.82M Buy
34,719
+10,458
+43% +$499K 0.43% 92
2016
Q2 		$1M Buy
24,261
+11,787
+94% +$513K 0.26% 145
2016
Q1 		$507K Buy
+12,474
New +$429K 0.16% 139

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Piermont Capital Management's FPRX Position: Q1 2017 in Review

Piermont Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 32,504 shares — an estimated $1.63M sold.

Piermont Capital Management first reported a position in FPRX in Q1 2016 and held it in 4 quarters. The position peaked at $1.82M in Q3 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Piermont Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Piermont Capital Management sold 32,504 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $1.63M.
  • Piermont Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 4 quarters.
  • Piermont Capital Management's Five Prime Therapeutics, Inc. position peaked at $1.82M in Q3 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Piermont Capital Management's 13F filing for Q1 2017, filed 11 May 2017.